2nd Symposium on Advances in Cancer Immunology and Immunotherapy, December 15 –17, 2016, Athens, Greece

AbstractThis is the 2nd Symposium of a series organized annually. It aims to integrate tumor immunology basic research with results from most recent clinical trials based on the use of anti-cancer agents targeting immune system components.
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research

Related Links:

Conditions:   Melanoma;   Non-Small Cell Lung Cancer Intervention:   Drug: Single Arm Sponsors:   Cytosite Biopharma Inc.;   Massachusetts General Hospital;   University of Alabama at Birmingham Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Abstract The complexity of the immune response and diversity of targets challenges conventional conceptual frameworks used in selecting and monitoring treatment with immune check-point inhibitors. The limitations of anatomic imaging in assessing response have been recognized. Varying patterns of response have been recognized. These patterns have different implications for the continuation and duration of therapy. Evidence supporting the role of 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography as a prognostic biomarker and in characterizing response is presented. An added benefit of this appr...
Source: Clinical Lung Cancer - Category: Cancer & Oncology Authors: Tags: PET Clin Source Type: research
(University of Bern) Killer cells of the immune system detect and kill infected cells or cancer cells. Researchers at the Institute of Pathology at the University of Bern have now discovered that the mechanism by which certain immune cells kill their target cells can also be used to control the killer cells themselves. This finding may be relevant to cancer immunotherapy.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
Publication date: Available online 17 November 2019Source: European Polymer JournalAuthor(s): Samson O. Aisida, Paul A. Akpa, Ishaq Ahmad, Ting-kai Zhao, M. Maaza, Fabian I. EzemaAbstractCancer cells are typified by proliferating mass of cells that grow faster than other smaller cell tissues within the body. Efforts to combat this effect through chemotherapy, radiotherapy, immunotherapy and surgery are still challenging. Magnetic Iron oxide nanoparticles (FeO-NPs) encapsulated with biopolymers as a local drug delivery system with the control via an external magnetic field has been widely used as a drug delivery system in c...
Source: European Polymer Journal - Category: Chemistry Source Type: research
Source: OncoTargets and Therapy - Category: Cancer & Oncology Tags: OncoTargets and Therapy Source Type: research
In the last years, immunotherapies have shown tremendous success as treatments for multiple types of cancer. However, there are still many obstacles to overcome in order to increase response rates and identify effective therapies for every individual patient. Since there are many possibilities to boost a patient’s immune response against a tumor and not all can be covered, this review is focused on T cell receptor-mediated therapies. CD8+ T cells can detect and destroy malignant cells by binding to peptides presented on cell surfaces by MHC (major histocompatibility complex) class I molecules. CD4+ T cells can also m...
Source: Frontiers in Genetics - Category: Genetics & Stem Cells Source Type: research
Molecules, Vol. 24, Pages 4192: ENPP1, an Old Enzyme with New Functions, and Small Molecule Inhibitors—A STING in the Tale of ENPP1 Molecules doi: 10.3390/molecules24224192 Authors: Kenneth I. Onyedibe Modi Wang Herman O. Sintim Ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1) was identified several decades ago as a type II transmembrane glycoprotein with nucleotide pyrophosphatase and phosphodiesterase enzymatic activities, critical for purinergic signaling. Recently, ENPP1 has emerged as a critical phosphodiesterase that degrades the stimulator of interferon genes (STING) ligand, cyclic GMP&am...
Source: Molecules - Category: Chemistry Authors: Tags: Review Source Type: research
Allogeneic hematopoietic stem cell transplantation (allo-SCT) is the most established and commonly used cellular immunotherapy in cancer care. It is the most potent anti-leukemic therapy in patients with acute myeloid leukemia (AML) and is routinely used with curative intent in patients with intermediate and poor risk disease. Donor T cells, and possibly other immune cells, eliminate residual leukemia cells after prior (radio)chemotherapy. This immune-mediated response is known as graft-versus-leukemia (GvL). Donor alloimmune responses can also be directed against healthy tissues, which is known as graft-versus-host diseas...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Canonical WNT/β-catenin signaling is involved in most of the mechanisms that lead to the formation and development of cancer cells. It plays a central role in three cyclic processes, which are the cell division cycle, the immune cycle, and circadian rhythms. When the canonical WNT pathway is upregulated as in cancers, the increase in β-catenin in the nucleus leads to activation of the expression of numerous genes, in particular CYCLIN D1 and cMYC, where the former influences the G1 phase of the cell division cycle, and the latter, the S phase. Every stage of the immune cycle is disrupted by the canonical WNT sign...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Immunotherapy, Ahead of Print.
Source: Immunotherapy - Category: Allergy & Immunology Authors: Source Type: research
More News: Allergy & Immunology | Cancer | Cancer & Oncology | Clinical Trials | Greece Health | Immunotherapy